Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow, Internal Medicine, University Hospitals of Cleveland 1987 - 1990
  • Resident, Internal Medicine, University Hospitals of Cleveland 1985 - 1987
  • Intern, Internal Medicine, University Hospitals of Cleveland 1984 - 1985
  • M.D., Duke University 1984
• 

  Previous Appointments & Affiliations

  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2008 - 2020
  • Consulting Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1998 - 2008
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1998
• Research
• 

  External Relationships

  • AbbVie Pharmaceuticals
  • Campbell University Schol of Osteopathic Medicine
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co. USA (not assoc'd with Merck KGaA)
  • Merck, Organon
  • Pfizer Inc.
  • Viatris
  • Viking Therapeutics
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
       Full Text  Link to Item
    • Sedwick, W. D., R. D. Anderson, J. Baxter, S. Donover, S. Schneiter, and M. L. Veigl. “Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.” Mutat Res 326, no. 1 (January 1995): 17–27. https://doi.org/10.1016/0027-5107(94)00155-x.
       Full Text  Link to Item
    • Veigl, M. L., S. P. Donover, R. D. Anderson, L. Akst, C. E. Sedwick, and W. D. Sedwick. “Effect of isopropyl-beta-D-thiogalactopyranosid induction of the lac operon on the specificity of spontaneous and doxorubicin-induced mutations in Escherichia coli.” Environ Mol Mutagen 26, no. 1 (1995): 16–25. https://doi.org/10.1002/em.2850260104.
       Full Text  Link to Item
    • Anderson, R. D., and N. A. Berger. “International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.” Mutat Res 309, no. 1 (August 1, 1994): 109–42. https://doi.org/10.1016/0027-5107(94)90048-5.
       Full Text  Link to Item
    • Anderson, R. D., M. L. Veigl, J. Baxter, and W. D. Sedwick. “Excision repair reduces doxorubicin-induced genotoxicity.” Mutat Res 294, no. 3 (October 1993): 215–22. https://doi.org/10.1016/0921-8777(93)90004-z.
       Full Text  Link to Item
    • Anderson, R. D., C. Y. Bao, D. T. Minnick, J. Baxter, M. L. Veigl, and W. D. Sedwick. “Sequencing of double-stranded polymerase chain reaction products for mutation analysis.” Mutat Res 288, no. 1 (July 1993): 181–85. https://doi.org/10.1016/0027-5107(93)90219-6.
       Full Text  Link to Item
    • Anderson, R. D., M. L. Veigl, J. Baxter, and W. D. Sedwick. “DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli.” Cancer Res 51, no. 15 (August 1, 1991): 3930–37.
       Link to Item
    • Anderson, R. D., M. L. Veigl, and W. D. Sedwick. “Rapid mapping of deletion and duplication mutations by the polymerase chain reaction.” Biochem Biophys Res Commun 170, no. 2 (July 31, 1990): 416–20. https://doi.org/10.1016/0006-291x(90)92107-b.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.